Australian Register of Therapeutic Goods (ARTG)
The ARTG is the public database of therapeutic goods that can be legally supplied in Australia. You can search the ARTG to find details of therapeutic goods approved for supply.
Information held in the ARTG includes product name and formulation details, and sponsor (company) and manufacturer details.
For more details and how to use the ARTG search function, go to Searching the Australian Register of Therapeutic Goods (ARTG).
Search results from the ARTG include Consumer Medicine Information (CMI), Product Information (PI) and Public Summary documents. Not all CMI and PI documents are available on this website.
Search for health products on our ARTG database
For a more detailed search, we have an ARTG visualisation tool. This has been developed for larger screens and Chrome browser.
Consumer and Product Information
Access to therapeutic goods not on the ARTG
As with many aspects of the regulatory framework, there are situations where special policies have been developed in response to the needs of particular people or circumstances. Information on these policies and the relevant procedures can be found at:
- Prescribe an unapproved therapeutic good (health practitioners)
- Personal importation scheme
- Clinical trials
- Accessing medicines during a medicine shortage
These schemes cannot be used to facilitate the commercial supply of therapeutic goods.
Latest alerts
-
Caruso's Natural Health Pty Ltd is recalling certain batches of WEE LESS, BLOAT EZE and ASHWAGANDHA 7500 due to suspected tampering.
-
There is a potential for insulin leakage with the Accu-Chek Spirit 3.15 ml cartridge system due to a manufacturing problem.
-
Insulet is advising they have received complaints of Omnipod DASH PDM/controller battery depletion as a result of the 3G network deactivation in the region.
Latest articles
-
Elemental impurities in traditional Chinese medicines (TCMs)
TCMs sold in Australia are carefully regulated to ensure safety and quality. -
TGA's decision to not register lecanemab (LEQEMBI)
TGA has made the decision not to register lecanemab (LEQEMBI) for the treatment of patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease and Mild Alzheimer's dementia (early Alzheimer's disease). -
Sponsors and manufacturers reminded about upcoming financial deadlines
A reminder about financial deadlines that are approaching for sponsors and manufacturers.
Latest publications
-
An overview of the Medicines Repurposing Program's purpose and history.